key: cord-0009376-fqzi840v
authors: Viboud, Cécile; Simonsen, Lone
title: Timely estimates of influenza A H7N9 infection severity
date: 2013-06-24
journal: Lancet
DOI: 10.1016/s0140-6736(13)61447-6
sha: 25b6f48e9b16f929e827258253ef02b3b7a7ff91
doc_id: 9376
cord_uid: fqzi840v

nan

WHO guidance, released in May, 2013, established that estimates of disease severity are key for risk assessment of novel infl uenza viruses. 1 Unfortunately, epidemiological assessment of severity is diffi cult in the context of an emerging disease, when estimates are most needed to guide pandemic response. The case fatality risk is an estimate of the proportion of patients with a specifi c disease who have died; however, both the numerator and denominator of this estimator are elusive. [2] [3] [4] Case detection is typically skewed towards patients with severe disease; laboratory-based case ascertainment can vary geographically and temporally; and there are delays between onset, death, and report ing, potentially leading to overestimation or under estimation of fatality risk. 2, 4 Much work has been done to refi ne estimates of case fatality risk in the wake of the 2003 outbreak of severe acute respiratory syndrome and the 2009 infl uenza pandemic. 2 Diff erent denominators have been con sidered, including patients who have been admitted to hospital, 5 symptomatic cases, 5 and all individuals with serological evidence of infection. 6 From a statistical point of view, survival analysis provides an appropriate framework to quantify case fatality with right-censored outcome data. 2, 5 In The Lancet, Hongjie Yu and colleagues assess the clinical severity of human infection with avian infl uenza A H7N9 virus on the basis of data from 123 patients with laboratory-confi rmed infection who were admitted to hospital between March and May, 2013, in mainland China. 5 They estimate that the fatality risk for all ages was 36% (95% CI 26-45), and note that nearly all patients were admitted to an intensive care unit, received mechanical ventilation, or died (83%, 76-90). 71 (58%) of the patients were aged at least 60 years, and fatality risk was higher for these individuals (49%, 36-63) than for younger patients (18%, 6-29; p=0·0019), as is typical of infl u enza infection. 6 To obtain an estimate of symptomatic case fatality risk, Yu and colleagues 5 extrapolated the total number of symptomatic individuals infected with avian infl uenza A H7N9 virus on the basis of the number of mild cases detected through routine infl uenza-like illness surveillance in Shanghai and Nanjing-the most aff ected cities. They estimate that the symptomatic case fatality risk could be between 160 (95% CI 63-460) and 2800 (1000-9400) per 100 000 symptomatic cases. This estimate is highly sensitive to assumptions about testing propensity, surveil lance coverage, and health-care seeking behaviour.

Use of near-real-time estimates of case fatality risk to guide policy is typically limited by broad uncertainty (table). During early assessment of 2009 pandemic infl uenza disease severity, 4 information about the fi rst 1100 laboratory-confi rmed cases produced a severity estimate of 4%, which is even higher than Yu and colleague's new estimates. 5 However, the 2009 estimate was soon downgraded by more than two orders of magnitude as information accumulated during the summer of 2009 (table) . Similarly, severity estimates for avian infl uenza A H7N9 virus will be refi ned as the fate of all patients admitted to hospital is resolved and as serological attack rates become available (attack rates could be generated from cross-sectional surveys because background population immunity is low 16 ) .

It is reassuring that head-to-head comparison of the fatality risk of admitted patients infected with avian infl uenza A H7N9 or H5N1 suggests a substantially milder disease course for H7N9. 7 Use of these estimates of case fatality risk to extrapolate the potential severity of a full pandemic would be tempting; however, whether global dissemination of these zoonotic infl uenza viruses would result in a catastrophic pandemic like that in 1918, or worse, or would mirror the mild 2009 pandemic (table) is impossible to predict.

A remaining question relates to the age distribution of symptomatic infections should a zoonotic infl uenza virus acquire person-to-person transmissibility. So far, the age distribution of reported cases of infection with avian infl uenza A H7N9 virus has been skewed towards old ages, which is probably explained by behavioural age diff erences in exposure to the animal reservoir. 17 The age distribution of cases would probably shift towards younger ages in a full pandemic, resulting in a diff erent and potentially decreased case fatality risk. Another issue would be to account for potential changes in disease severity as the virus rapidly evolves. Although conventional wisdom stipulates that virulence attenuates as a pathogen adapts to a new host, animal experiments suggest that infl uenza virulence could increase simultaneously with genetic drift. 18 Furthermore, evidence from the 1918 pandemic suggests that the situation can escalate: case fatality risk increased by six times from the summer to the autumn of 1918. 19 The good news is that numbers of cases of avian infl uenza A H7N9 virus infection have stalled, probably in response to pre-emptive closures of live bird markets. However, the threat of this virus persists, and continued monitoring of infections, together with near-real-time estimation of case fatality risk and serological surveys, remains crucial. Investment in robust hospital surveillance of respiratory infections in a few globally sampled sites, combined with laboratory testing, would help to produce comparative severity estimates for novel and existing viral threats. Yu and colleagues 5 have provided the best severity estimates for avian infl uenza A H7N9 virus in view of the available information at this point in time; however, public health experts will have to make policy decisions on the basis of uncomfortably broad confi dence limits. Although progress has been made in reducing global maternal mortality, an estimated 287 000 women still died in 2010. 1 Maternal mortality disproportionately aff ects families living in low-income and middleincome countries, and most of these deaths are preventable. Eff ective and cheap interventions exist to prevent death from the major causes, including haemor rhage, hypertensive disease, sepsis, and septic abortion. What is lacking is evidence on imple mentation in view of local contexts, resource constraints, and cultural norms. 2 For many years, WHO has championed multidisciplinary maternal mortality audit as essential for reducing deaths. 3 For audit to achieve change, there must be willingness to identify problems, with leadership capable and motivated to institute changes. Audit involves far more than just counting deaths. Perhaps not surprisingly given the complexity of multidisciplinary audit, to date evidence from randomised trials that show a reduction in maternal deaths has been poor. 4 In The Lancet, Alexandre Dumont and colleagues address this knowledge gap with fi ndings from the QUARITE trial. 5 This cluster-randomised trial was done in 46 hospitals across Senegal and Mali. The authors assessed a complex intervention of maternal mortality audits, leadership development, training in emergency obstetric care, and outreach health practitioner education. Data for more than 190 000 women were collected over 4 years, giving the study power to detect a change in mortality. The intervention was based on the Society of Obstetricians and Gynaecologists of Canada ALARM (Advances in Labour And Risk Management) International Program. This programme uses adult learning techniques to teach essential evidence-based obstetric skills. 6 Hospitals allocated to the control group did not partake in the intervention and continued usual care.

The results showed a 15% greater reduction in maternal deaths in the intervention compared with the control hospitals over 4 years (odds ratio [OR] 0·85, 95% CI 0·73-0·98, p=0·0299). 5 This reduction was less

National Institutes of Health) for helpful comments. LS is a member of the Severity Assessment Plan Technical Working Group initiated by WHO in 2013, and acknowledges support from the RAPIDD program of the Science and Technology Directorate

Pandemic infl uenza risk management: WHO interim guidance

Assessing the severity of the novel infl uenza A/H1N1 pandemic

The severity of pandemic H1N1 infl uenza in the United States

Improving the evidence base for decision making during a pandemic: the example of 2009 infl uenza A/H1N1

Human infection with avian infl uenza A H7N9 virus: an assessment of clinical severity

The infection attack rate and severity of 2009 pandemic H1N1 infl uenza in Hong Kong

Comparative epidemiology of human infections with avian infl uenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confi rmed cases

Avian infl uenza A(H5N1) in humans: new insights from a line list of World Health Organization confi rmed cases

1918 infl uenza: the mother of all pandemics

Pandemic potential of a strain of infl uenza A (H1N1): early fi ndings

Pandemic infl uenza A(H1N1)v in New Zealand: the experience from

Infection and death from infl uenza A H1N1 virus in Mexico: a retrospective analysis

Risk factors for severe illness with 2009 pandemic infl uenza A (H1N1) virus infection in China

Epidemiological characteristics of 2009 (H1N1) pandemic infl uenza based on paired sera from a longitudinal community cohort study

Changes in severity of 2009 pandemic A/H1N1 infl uenza in England: a Bayesian evidence synthesis

Serologic study for infl uenza A (H7N9) among high-risk groups in China

Preliminary inferences on the age-specifi c seriousness of human disease caused by avian infl uenza A(H7N9) infections in China

N-linked glycosylation of the hemagglutinin protein infl uences virulence and antigenicity of the 1918 pandemic and seasonal H1N1 infl uenza A viruses

Epidemiologic characterization of the 1918 infl uenza pandemic summer wave in Copenhagen: implications for pandemic control strategies